HomeNDC LookupDrug shortages › Deferiprone Tablet

Deferiprone Tablet shortage

Deferiprone Tablet is currently listed in shortage by the FDA. The FDA lists 1 affected product. This page was last refreshed from FDA data on Sep 22, 2026.

To Be Discontinued ⚠ Supply risk: High Hematology 1 product 319 days First posted Nov 7, 2025 Updated Nov 7, 2025
Here’s the bottom line

Chiesi USA is stopping production of deferiprone 500 mg tablets, and this change may be permanent. Other makers — including Hikma, Sun Pharmaceutical, and Dr. Reddy's — still list deferiprone tablets in both 500 mg and 1000 mg strengths, as well as Ferriprox (deferiprone) 1000 mg tablets.

Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).

Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →
1
Affected NDCs
1
Reporting manufacturers
0/1
Reporting mfrs supplying
0/1
Affected strengths supplied
319
Days in shortage
Source: FDA Drug Shortages Database API (openFDA). Last refreshed Sep 22, 2026 · yesterday

What’s in shortage — at a glance

These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Deferiprone Tablet. Other makers that haven’t reported a problem are shown in the green card below.

Availability of affected NDCs
From the FDA shortage report
1 NDCs
To be discontinued 1
Affected strengths still supplied
Among manufacturers reporting this shortage
0/1 strengths
No supply 1
FDA-reporting manufacturers with supply
Among manufacturers reporting this shortage
0/1 makers
No supply 1
✓ Other manufacturers not reporting a shortage
Still-marketed Deferiprone Tablet from companies that have not filed an FDA shortage — these are not counted in the figures above. Stock can still vary by pharmacy.
Hikma Pharmaceuticals USA Inc. Chiesi USA, Inc. Sun Pharmaceutical Industries, Inc. DR. REDDY'S LABORATORIES, INC.
Plus 1 alternative dosage form of Deferiprone.
See all other options & details →
Shortage timeline
  1. Nov 7, 2025
    Currently in shortage
    1 of 1 product affected.
  2. Nov 7, 2025
    First reported to the FDA
    1 product first listed.

Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.

What exactly is on backorder — by manufacturer

Manufacturer: Chiesi USA, Inc. 📞 888-466-6505 1 NDC click to expand
Status NDC / product Strength Availability Related information Reason
To Be Discontinued Ferriprox, Tablet, 500 mg (NDC 10122-100-10) NDC 10122-0100-10 Discontinuation of the manufacture of the drug.

These rows are manufacturer reports to the FDA for Deferiprone Tablet — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Deferiprone Tablet? options further down this page.

Why is Deferiprone Tablet in shortage?

Chiesi USA has reported to the FDA that they are permanently stopping the manufacture of their Ferriprox 500 mg tablets. This specific product — the 500 mg tablet form made by Chiesi USA — will no longer be produced by them going forward.

It's worth knowing that Chiesi USA did not share a more specific public reason for why they made this decision — just that manufacturing of this product is being discontinued. This report only reflects what Chiesi USA has filed with the FDA, so it speaks only to their version of this 500 mg tablet.

Based on the manufacturer-reported reason(s) and notes on file with the FDA for Deferiprone Tablet, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.

What should I do if I take Deferiprone Tablet?

Deferiprone tablets are currently on the FDA drug-shortage list, and I want to walk you through what this means for you.

The strength on this record is the 500 mg tablet, and right now no available source is reported for it from the manufacturer that filed this shortage. There are no other strengths listed as still in supply on this particular record.

The reason given is that the manufacturer (Chiesi USA, maker of the brand Ferriprox) has marked this product as to be discontinued — meaning they are stopping production. Because this is a discontinuation rather than a temporary delay, this supply problem may be permanent for that maker, with no estimated recovery date. Importantly, this report reflects only one manufacturer; the same medicine may still be available from other companies.

Here is what I suggest:

  • Do not stop, skip, or change your dose on your own.
  • Ask your pharmacy to check wholesalers and other manufacturers — deferiprone 500 mg is listed as available from other makers (such as Hikma, Sun Pharmaceutical, and Dr. Reddy's), though it may not be in local stock.
  • Because the brand version is being discontinued, talk with your prescriber or pharmacist about your options going forward.

The manufacturer contact number is listed on this page for reference; pharmacies usually handle those calls.

See “Where else can I get Deferiprone Tablet?” below ↓ The same medicine from manufacturers not reporting a shortage, alternative dosage forms, and therapeutic equivalents with pricing.
If you are a patient:
  • Don’t stop or change the medication on your own — talk to your prescriber first.
  • If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
  • Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
  • Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Keep reading
Our full Deferiprone guide

Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.

Read the Deferiprone guide →

Where else can I get Deferiprone Tablet?

FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Deferiprone Tablet is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.

Same medicine, other manufacturers (not reported short)

Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:

ProductStrengthForm / routeManufacturerNDC
Deferiprone DEFERIPRONE 500 mg/1 Tablet, Coated · Oral Hikma Pharmaceuticals USA Inc. 00054-0576-25
Deferiprone DEFERIPRONE 1000 mg/1 Tablet, Coated · Oral Hikma Pharmaceuticals USA Inc. 00054-0711-19
Ferriprox DEFERIPRONE 1000 mg/1 Tablet, Film Coated · Oral Chiesi USA, Inc. 10122-0103-05
Ferriprox DEFERIPRONE 1000 mg/1 Tablet · Oral Chiesi USA, Inc. 10122-0104-01
Deferiprone DEFERIPRONE 500 mg/1 Tablet · Oral Sun Pharmaceutical Industries, Inc. 51672-4196-01
Deferiprone DEFERIPRONE 1000 mg/1 Tablet · Oral Sun Pharmaceutical Industries, Inc. 51672-4237-04
Deferiprone DEFERIPRONE 1000 mg/1 Tablet, Coated · Oral DR. REDDY'S LABORATORIES, INC. 75907-0348-50
Deferiprone DEFERIPRONE 500 mg/1 Tablet, Coated · Oral DR. REDDY'S LABORATORIES, INC. 75907-0349-01

Alternative dosage forms of Deferiprone

A different form of the same drug (for example a solution when capsules are short). A form change is a clinical decision — ask your prescriber:

Therapeutic equivalents & pricing 4 productsclick to expand

Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.

ProductManufacturerPackageNADAC $/unitAB ratingAvailability
Deferiprone 500 mgNDC 00054-0576-25 Hikma 100 tablets AB FDA listed
Deferiprone 500 mgNDC 51672-4196-01 Sun 100 tablets AB FDA listed
Deferiprone 500 mgNDC 75907-0349-01 DR. 100 tablets AB FDA listed
Ferriprox 500 mgNDC 10122-0100-10 Chiesi 100 tablets AB FDA listed

Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.

Other drugs in the same treatment class

These are different medicines — not other versions of Deferiprone Tablet — that fall in the same broad treatment class (metallic poison,agents to treat) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.

Identity & classification

GCN Seq No 046924
GCN 84849
HICL code 018544
Ingredient (HICL) Deferiprone
HIC1 code C
Therapeutic class — broad (HIC1) Electrolyte Balance/Metabolism/Nutrition
HIC2 code C8
Therapeutic class — intermediate (HIC2) Antidotes To Poisons
HIC3 code C8A
Therapeutic class — specific (HIC3) Metallic Poison,Agents To Treat
AHFS code 64:00.00.00
AHFS class Heavy Metal Antagonists
FDB label name FERRIPROX 500 MG TABLET
FDB brand name Ferriprox
Legend status F — Federal legend — prescription drug or device
Where does this data come from?
Identity codes come from First Databank (FDB) (HICL ingredient, HIC1–3 therapeutic-class hierarchy, GCN, AHFS class, legend status) and Medi-Span GPI, mapped from a representative affected NDC. Licensed reference data — for identification only.

Other hematology shortages

Deferiprone Tablet shortage FAQs

Is Deferiprone Tablet in shortage?
Yes — the FDA currently lists Deferiprone Tablet in shortage (status: “To Be Discontinued”, first reported Nov 7, 2025). 1 of 1 product is affected. This is national, manufacturer-reported data, so your pharmacy may still have stock.
Which products are affected?
Ferriprox, Tablet, 500 mg (NDC 10122-100-10) (NDC 10122-0100-10). The full per-NDC list (availability, manufacturer and status) is in the table above — each NDC links to its own page.
When will Deferiprone Tablet be available again?
The FDA does not publish a guaranteed restock date, and no estimated-recovery note is on file. Availability can change daily — confirm with your pharmacy.
Can I still get Deferiprone somewhere?
Other manufacturers (Hikma Pharmaceuticals USA Inc., Chiesi USA, Inc., Sun Pharmaceutical Industries, Inc. and others) still market it and have not reported a shortage. 1 alternative dosage form of Deferiprone is also listed. See “Where else can I get Deferiprone Tablet?” above — stock still varies by pharmacy.
What should I do if I take Deferiprone Tablet?
Don’t stop or change it on your own. Ask your pharmacist whether they can order it from another manufacturer or a different strength/package size, and ask your prescriber about a long-term plan before your supply runs out.

Still have a question about the Deferiprone Tablet shortage?

Ask a pharmacist about this shortage →
How to read the Supply-Risk rating
Low (1–2)Multiple manufacturers still supplying and most strengths or pack sizes sourceable.
Medium (3)Some constraint — fewer suppliers or a notable share of NDCs unavailable.
High (4–5)Down to a single source, most strengths or pack sizes unsourceable, or a long-running outage.
Where does this data come from?
Shortage records come from the FDA Drug Shortages Database API via openFDA (/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.
Data structure & sourcing designed and verified by Dr. Brian Staiger, PharmD.
← Back to all current drug shortages